Evidence showed that the proportion of PD-L1-positive tumor cells in PLELC is higher than that in lung adenocarcinoma or squamous cell lung carcinoma (21–23), offering potential for anti-PD-1/PD-L1 therapy for this distinctive subtype of NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.